Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,852.00
Bid: 7,851.00
Ask: 7,853.00
Change: 66.00 (0.85%)
Spread: 2.00 (0.03%)
Open: 7,770.00
High: 7,871.00
Low: 7,700.00
Yest. Close: 7,786.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UPDATE 1-J&J to cooperate in study of rare clots linked to COVID-19 vaccine, German scientist says

Tue, 20th Apr 2021 20:35

(Adds details of collaboration, scientific paper)

By John Miller

ZURICH, April 20 (Reuters) - A German scientist studying
extremely rare blood clots linked to AstraZeneca's
COVID-19 vaccine said on Tuesday Johnson & Johnson has
agreed to work with him on the research after similar serious
side effects emerged in recipients of its shot.

Andreas Greinacher, a transfusion medicine expert at
Greifswald University, announced the collaboration after the
European Medicines Agency said it would add a label to J&J's
vaccine warning of unusual blood clots with low platelet counts.
AstraZeneca's shot has a similar warning.

As with AstraZeneca, the EMA said benefits of getting J&J's
shot still outweigh the clotting risk, a position Greinacher
backs, too.

Greinacher, who on Tuesday released a new paper https://www.researchsquare.com/article/rs-440461/v1
offering a potential explanation for the complications, wants
J&J vaccine samples to study in his lab. Since mid-March his
team has been analyzing specimens from people who suffered clots
after getting AstraZeneca's shot.

"We agreed today with (J&J) that we will work together,"
Greinacher said during a news conference. "My biggest need,
which I've expressed to the company, is I would like to get
access to the vaccine, because the J&J vaccine is not available
in Germany."

Johnson & Johnson did not immediately respond to a request
for comment.

The EMA said on Tuesday it suspects the vaccine may trigger
an unwanted immune response, but safety committee chairwoman
Sabine Straus said it has not identified specific risk factors.

"It would be very helpful if we know beforehand, whether it
might be some kind of genetic disorder, or something else in the
blood vessels," Straus told reporters.

Greinacher does not believe such a prognostic test is
likely, based on experience with a similar disorder called
heparin-induced thrombocytopenia that has defied efforts to
identify why some people may be predisposed to the serious
condition.

"We even completely gene-sequenced 3,000 of these patients,
and we couldn't find a genetic predisposition," he said.

In Greinacher's new, not yet peer-reviewed, paper he
suggests the technology behind AstraZeneca's shot, some of its
ingredients and the powerful immune reaction it induces, may
contribute to a cascade of events that overpowers numerous
mechanisms that normally keep the human immune system under
control.

Both the AstraZeneca and J&J vaccines use a common cold
virus, albeit different ones, to ferry coronavirus proteins to
cells to produce an immune response.

"Individuals are different, and only if by coincidence, nine
or 10 weaknesses are coming together, then we have a (problem),"
Greinacher said. "Otherwise, our in-built security systems block
it, and keep us safe."

(Reporting by John Miller in Zurich and Julie Steenhuysen in
Chicago; Editing by Bill Berkrot)

More News

Mexico's first locally produced AstraZeneca vaccines to be ready in May

MEXICO CITY, May 13 (Reuters) - Mexico's Finance Minister Arturo Herrera said on Thursday that the first batch of AstraZeneca COVID-19 vaccines bottled in Mexico would be ready later this month, after delays in starting operations at a local fact...

Today 19:18

UPDATE 1-Quebec stops offering first doses of AstraZeneca vaccine

(Adds background)TORONTO, May 13 (Reuters) - The Canadian province of Quebec will no longer offer first doses of the AstraZeneca COVID-19 vaccine as of Thursday, but will offer second doses using current supplies and future deliveries, the provinc...

Today 17:36

UPDATE 1-Egypt receives 2.2 mln AstraZeneca and Sinopharm vaccine doses

(Adds Sinopharm delivery, details)CAIRO, May 13 (Reuters) - Egypt has received a batch of more than 1.7 million doses of the AstraZeneca vaccine through the COVAX initiative and a separate shipment of 500,000 Sinopharm vaccine doses from China, th...

Today 17:12

Quebec to stop offering first shots of AstraZeneca vaccine

TORONTO, May 13 (Reuters) - The Canadian province of Quebec will no longer offer first doses of the AstraZeneca COVID-19 vaccine as of Thursday, but will offer second doses using current supplies and future deliveries, the province's health minis...

Today 16:30

RPT-INSIGHT-Top scientists question the need for COVID-19 booster shots

(Repeats to fix formatting without change to text)By Julie Steenhuysen and Kate KellandMay 13 (Reuters) - COVID-19 vaccine developers are making ever bolder assertions that the world will need yearly booster shots, or new vaccines to tackle concern...

Today 14:01

INSIGHT-Top scientists question the need for COVID-19 booster shots

By Julie Steenhuysen and Kate Kelland May 13 (Reuters) - COVID-19 vaccine developers are making ever bolder assertions that the world will need yearly booster shots, or new vaccines to tackle concerning coronavirus variants, but some scie...

Today 11:00

Egypt receives 1.7 mln AstraZeneca vaccine doses through COVAX

CAIRO, May 13 (Reuters) - Egypt has received a batch of more than 1.7 million doses of the AstraZeneca vaccine through the COVAX initiative, the health ministry said on Thursday.Egypt received its first COVAX delivery of 854,000 AstraZeneca doses...

Today 09:29

UPDATE 3-Taiwan proposes $7.5 bln in spending as domestic COVID-19 cases rise

(Adds Taiwan president comments)TAIPEI, May 13 (Reuters) - Taiwan's government proposed on Thursday an extra T$210 billion ($7.5 billion) in spending to help the economy deal with the COVID-19 pandemic, as it reported 13 new domestic cases amid a ...

Today 02:09

Delaying second COVID-19 vaccine doses can help reduce deaths - study

LONDON, May 12 (Reuters) - Giving a first dose of COVID-19 vaccine but delaying a second dose among people younger than 65 could lead to fewer people dying of the disease, but only if certain conditions are met, a predictive modelling study showed...

12 May 21 23:30

MEDIA-Russian plant to produce first AstraZeneca vaccine batches in June - RBC

May 12 (Reuters) -* Russian pharmaceutical firm R-Pharm will in June start producing the first doses in Russia of the COVID-19 vaccine developed by AstraZeneca and Oxford University, RBC magazine reported on Wednesday, citing the company's direct...

12 May 21 18:39

UPDATE 1-Swiss aim to re-open economy, donate AstraZeneca COVID-19 shots

(Adds comment from health minister)By John MillerZURICH, May 12 (Reuters) - Switzerland aims to expand its economic re-opening and may donate millions of AstraZeneca COVID-19 vaccine doses to developing countries as the Alpine nation grows increas...

12 May 21 16:05

UPDATE 1-More data needed before COVID-19 vaccine booster call - EU regulators

(Adds details, quotes, background)May 12 (Reuters) - More clinical and real-world data is needed on how well and for how long COVID-19 vaccines are protective before any decisions should be made on offering third or booster doses, Europe's drug re...

12 May 21 14:46

Swiss consider donating 3 mln doses of AstraZeneca vaccine to COVAX

ZURICH, May 12 (Reuters) - Switzerland is considering donating 3 million of the 5.4 million AstraZeneca COVID-19 vaccine doses it has reserved to the COVAX vaccine sharing programme, Swiss Health Minister Alain Berset said on Wednesday."The (Astr...

12 May 21 14:39

Wednesday broker round-up

(Sharecast News) - Air Partner: Canaccord reiterates buy with a target price of 100p.

12 May 21 13:55

More data needed before COVID-19 vaccine booster decisions -EU regulators

May 12 (Reuters) - More clinical and real-world data is needed on how well and for how long COVID-19 vaccines are protective before any decisions should be made on offering third or booster doses, Europe's drug regulators said on Wednesday.Speakin...

12 May 21 13:37

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.